Novel collagen V-reactive natural Th17 cells in hypoxic pulmonary hypertension
Novel collagen V-reactive natural Th17 cells in hypoxic pulmonary hypertension
批准号:
10267902
负责人:
Laura V Gonzalez Bosc
金额:
$37.88万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-24 至 2022-08-31
关键词:
Acute Lung InjuryAffectAltitudeAlveolarAntigensAtherosclerosisAutoantigensAutoimmunityBlood PressureBronchiolitisCD4 Positive T LymphocytesCause of DeathCell MobilityCellsCellular ImmunityCenters for Disease Control and Prevention (U.S.)ChronicChronic Obstructive Airway DiseaseChronic lung diseaseCollagenCollagen Type VCytotoxic T-LymphocytesDendritic CellsDevelopmentDiseaseDisease ProgressionEquilibriumEtiologyExcisionExposure toGenerationsHeartHelper-Inducer T-LymphocyteHomeostasisHomingHumanHypoxiaImmuneImmune systemImmunityImmunotherapyInflammationInflammatoryInflammatory ResponseKnowledgeLeadLifeLigandsLungLung TransplantationLung diseasesMalignant NeoplasmsMediatingMedicalMetalloproteasesMucous MembraneMusPathogenesisPathway interactionsPhenotypePlayPulmonary FibrosisPulmonary HypertensionPulmonary artery structurePumpRegimenRegulatory T-LymphocyteResearchRodentRoleSentinelSignal TransductionSiteSourceT-LymphocyteTestingThymus GlandTunica AdventitiaUnited StatesUp-RegulationWorld Health Organizationarterial remodelingautoreactive T cellautoreactivitybeta-Chemokineschemokinechemokine receptorfetalgamma-Chemokinesindexinginterstitiallung hypoxiamortality riskneoantigensnovelorgan injurypathogenperipheral tolerancepreventreceptorresponsetherapy developmenttraffickingγδ T cells
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Hypoxic pulmonary hypertension (PH) is a progressive and often fatal consequence of chronic lung
diseases, chronic exposure to high altitude and acute lung injury. We have demonstrated that TH17
cells, a pro-inflammatory T helper (TH) cell (CD4+) subset, are localized in the perivascular region of
pulmonary arteries. These cells contribute to CH-induced PH. However, whether immunity to self-
antigens contributes to disease progression is unknown. Type V collagen (col V) is normally
sequestered within the lung interstitium and therefore, hidden from the immune system. Hypoxia could
lead to exposure of col V and be a source of antigen. Col V cellular immunity contributes to TH17-
dependent obliterative bronchiolitis post-lung transplant, atherosclerosis and interstitial lung fibrosis.
However, it is unknown whether colV cellular immunity plays a role in the TH17 cell-dependent
perivascular inflammation that contributes to CH-induced PH and the mechanism of TH17 cells homing.
It is also unknown if this TH17 cells belong to the natural occurring (nTH17) subset. Therefore, we
propose the novel hypothesis that nTH17-mediated PH develops as a result of increased col V-reactive
nTH17 cells and reduced peripheral tolerance to col V. We also propose that this mechanism requires
nTH17 cell trafficking to the perivascular region under the guidance of C-C motif chemokine ligand 2
(CCL2)/C-C chemokine receptor type 2 (CCR2) signaling. We will pursue the following aims:
Specific Aim 1: To identify lung-associated self-antigens induced or exposed by CH. Hypothesis: Col V
is a lung-associated self-antigen uncovered by CH that triggers nTH17 cell-mediated perivascular
inflammation.
Specific Aim 2: To identify the mechanism of nTH17 cell homing to the perivascular region in response
to CH. Hypothesis: CCL2/CCR2 signaling drives nTH17 cell homing to the perivascular region in
response to CH.
Specific Aim 3: To determine the contribution of loss of peripheral tolerance to self-antigens in PH.
Hypothesis: A loss in the normal balance between col V-reactive nTH17 cells and nTregs due to nTreg
transition to an nTH17 phenotype contributes to the development of PH.
Completion of these studies will identify the self-antigens or neo-antigens exposed by CH, determine
triggers for nTH17 cell-homing to the pulmonary perivascular region, and the role of peripheral
tolerance in this pathway. This groundbreaking study will also facilitate the development of therapies
to selectively inhibit the generation of autoreactive T cells and their trafficking to the site of
inflammation without affecting the capacity of the host to mount a proper inflammatory response to
pathogens.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NFATc3 in chronic hypoxic pulmonary hypertension
-
批准号:7839262
-
项目类别:
-
资助金额:$8.71万
-
财政年份:2009
-
负责人:Laura V Gonzalez Bosc
-
依托单位:
NFATc3 in chronic hypoxic pulmonary hypertension
-
批准号:7534997
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2007
-
负责人:Laura V Gonzalez Bosc
-
依托单位:
NFATc3 in chronic hypoxic pulmonary hypertension
-
批准号:7746406
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2007
-
负责人:Laura V Gonzalez Bosc
-
依托单位:
NFATc3 in chronic hypoxic pulmonary hypertension
-
批准号:7367250
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2007
-
负责人:Laura V Gonzalez Bosc
-
依托单位:
NFATc3 in chronic hypoxic pulmonary hypertension
-
批准号:8197297
-
项目类别:
-
资助金额:$37.13万
-
财政年份:2007
-
负责人:Laura V Gonzalez Bosc
-
依托单位:
海外基金